Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease.

Autor: Motter JN; Department of Psychiatry Memory Disorders Center and the Division of Geriatric Psychiatry at the New York State Psychiatric Institute New York USA.; Columbia University Irving Medical Center New York USA., Liu X; Mailman School of Public Health of Columbia University New York USA., Qian M; Mailman School of Public Health of Columbia University New York USA., Cohen HR; Department of Psychiatry Memory Disorders Center and the Division of Geriatric Psychiatry at the New York State Psychiatric Institute New York USA., Devanand DP; Department of Psychiatry Memory Disorders Center and the Division of Geriatric Psychiatry at the New York State Psychiatric Institute New York USA.; Columbia University Irving Medical Center New York USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (Amsterdam, Netherlands) [Alzheimers Dement (Amst)] 2021 Mar 31; Vol. 13 (1), pp. e12158. Date of Electronic Publication: 2021 Mar 31 (Print Publication: 2021).
DOI: 10.1002/dad2.12158
Abstrakt: Introduction: This study evaluated acute change in odor identification following atropine nasal spray challenge, and 8-week change in odor identification ability, as a predictor of long-term improvement in patients with mild to moderate Alzheimer's disease (AD) who received open-label cholinesterase inhibitor treatment.
Methods: In patients with clinical AD, the University of Pennsylvania Smell identification Test (UPSIT) was administered before and after an anticholinergic atropine nasal spray challenge. Patients were then treated with donepezil for 52 weeks.
Results: In 21 study participants, acute atropine-induced decrease in UPSIT was not associated with change in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) or Selective Reminding Test (SRT). Decline in odor identification performance from baseline to week 8 was indicative of a future decline in cognitive performance over 52 weeks.
Discussion: Change in odor identification with atropine challenge is not a useful predictor of treatment response to cholinesterase inhibitors. Short-term change in odor identification performance needs further investigation as a potential predictor of cognitive improvement with cholinesterase inhibitor treatment.
Competing Interests: D. P. Devanand: Consultant to Eisai, Genentech, Axovant, Astellas, Acadia. Research support: NIA, DOD, Avanir.
(© 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: